Targets › EHMT2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.
Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. (UniProt, Q96KQ7)
Open in Phaseline: the race on EHMT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | zemetostat G9a/GLP histone methyltransferase inhibitor | EHMT2 | Phase 2 | Soft Tissue Sarcoma | Nov 2028 |
Soft Tissue Sarcoma (1)
small molecule (1)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.